Entera Bio Ltd. (ENTX) Stock Ticker
ENTX right now
Market factors today
Unlock the full ENTX picture
About Entera Bio Ltd.
Entera Bio Ltd. is a biopharmaceutical firm in the clinical development phase, dedicated to creating and marketing oral medications composed of large molecules, addressing medical conditions that currently lack adequate treatments. Its primary experimental drugs are EB612, currently undergoing Phase II clinical assessment for hypoparathyroidism, and EB613, which has concluded Phase II studies for osteoporosis and is now in Phase I trials for treating non-healing bone fractures. Furthermore, the company holds a collaborative research and licensing pact with Amgen Inc. aimed at identifying and advancing potential therapeutic compounds for inflammatory conditions and other grave ailments. Established in 2009, Entera Bio Ltd. operates from its headquarters in Jerusalem, Israel.
ENTX stock facts
| Ticker symbol | ENTX |
| Exchange | NASDAQ Capital Market |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market cap | $135.3M |
| CEO | Miranda J. Toledano |
| Employees | 21 |
| Headquarters | Jerusalem, JM, IL |
| IPO date | 2018-06-28 |
| Website | www.enterabio.com |
What you can see for ENTX on Tickr
Live ENTX price chart with overlays, the options chain, implied move, IV rank, options flow and Strategy Lab, financial statements and consensus estimates, analyst ratings, catalysts, news with AI scoring, and an AI chat that has read the ENTX report.
Rankings
FAQ
What is the ticker symbol for Entera Bio Ltd.?
The ticker symbol for Entera Bio Ltd. is ENTX, listed on the NASDAQ Capital Market.
What is ENTX?
Entera Bio Ltd. is a biopharmaceutical firm in the clinical development phase, dedicated to creating and marketing oral medications composed of large molecules, addressing medical conditions that currently lack adequate treatments. Its primary experimental drugs are EB612, currently undergoing Phase II clinical assessment for hypoparathyroidism, and EB613, which has concluded Phase II studies…